Related Experiment Video
Updated: Jan 30, 2026

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
Comments on the most important and recent studies involving PCSK9i
Abstract:
The paper provides a brief overview of the key studies focused on PCSK9 inhibitors. It mainly examines positive results of the FOURIER studies on evolocumab, the SPIRE study on boccocizumab and the ODYSSEY Outcomes study on alirocumab. All these studies have not only shown a significant decrease in LDL-cholesterol levels, but also the reduction of cardiovascular events just correlating with these levels. The treatment leading to a dramatic drop in LDL-cholesterol levels was safe and well tolerated by patients. All the studies provided with comments demonstrate a positive impact of biological treatment of hypercholesterolemia on cardiovascular disease and confirm validity of the hypothesis saying “the lower the better”, at least for LDL-cholesterol. In conclusion, Professor Braunwalds hypothesis is mentioned saying that this treatment might eventually lead to as much as eradication of atherothrombotic cardiovascular diseases. Key words: alirocumab - bococizumab - evolocumab - FOURIER - cardiovascular disease - LDL-cholesterol - ODYSSEY Outcomes - SPIRE.
Insights
New PCSK9 inhibitors like evolocumab and alirocumab significantly lower LDL-cholesterol and reduce cardiovascular events. This biological treatment for hypercholesterolemia is safe and effective, supporting the "lower is better" hypothesis.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Hypercholesterolemia is a major risk factor for cardiovascular disease.
- PCSK9 inhibitors represent a novel class of lipid-lowering agents.
- Previous treatments have limitations in achieving target LDL-cholesterol levels.
Purpose of the Study:
- To review key studies on PCSK9 inhibitors.
- To evaluate the efficacy and safety of evolocumab, bococizumab, and alirocumab.
- To assess the impact of these inhibitors on cardiovascular events.
Main Methods:
- Review of pivotal clinical trials: FOURIER (evolocumab), SPIRE (bococizumab), and ODYSSEY Outcomes (alirocumab).
- Analysis of data on LDL-cholesterol reduction and cardiovascular event rates.
- Assessment of patient safety and tolerability profiles.
Main Results:
- All studied PCSK9 inhibitors demonstrated significant reductions in LDL-cholesterol.
- Cardiovascular event reduction was observed and correlated with LDL-cholesterol levels.
- The treatments were generally safe and well-tolerated by patients.
Conclusions:
- PCSK9 inhibitors provide a positive impact on managing hypercholesterolemia and cardiovascular disease.
- The "lower is better" hypothesis for LDL-cholesterol is supported by these findings.
- This therapeutic approach may significantly reduce atherothrombotic cardiovascular diseases.
More Related Videos
Related Concept Videos
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Case Studies
Imaging Studies I: Kidney, Ureter, and Bladder Studies
Longitudinal Studies
Observational Studies
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...
Studying the Cytoskeleton

